Showing papers in "Value in Health in 2005"

TL;DR: A consensus emerged on a broad approach, along with a detailed critique of the strengths and weaknesses of the differing methodologies in this review of translation and cultural adaptation of patient-reported outcome measures.

TL;DR: Trial-based cost-effectiveness studies have appeal because of their high internal validity and timeliness and improving the quality and uniformity of these studies will increase their value to decision makers who consider evidence of economic value along with clinical efficacy when making resource allocation decisions.

TL;DR: Evaluated construct validity of the Treatment Satisfaction Questionnaire for Medication was evaluated using structural equation modeling and discriminant analysis demonstrated the superior classification power of the hierarchical model of treatment satisfaction over the discrete attribute model when predicting medication discontinuation.

TL;DR: The indirect excess cost due to unemployment is the largest component of overall schizophrenia excess annual costs.

TL;DR: Both persistence and adherence with medication treatment were suboptimal for chronic OAB/UI patients identified in this study, and it is suggested that persistence and treatment discontinuation remains problematic for the Oab/UI population.

TL;DR: A probabilistic model is presented that characterizes the uncertainty in the input parameters of their model as probability distributions and generates a joint distribution in the incremental costs and effect of the input para-meter uncertainty that can be summarized using cost-effectiveness acceptability curves.

TL;DR: Adherence to methodological and reporting practices in published CUAs is improving, although many studies still omit basic elements, and an impact in methodological practices used in US-based CUAs in accordance with recommendations of the USPCEHM is suggested.

TL;DR: All five face-to-face smoking cessation interventions were cost-effective compared with current practice, and minimal GP counseling was even cost-saving.

TL;DR: It is shown that cost-effectiveness results for pharmaceuticals vary from country to country in Western Europe and that these variations are not systematic; the lessons for inferring generalizability are not straightforward, although the implications of variation for decision making depend critically on the cost-Effectiveness thresholds applying in Western European.

TL;DR: This analytical framework is important because it addresses two fundamental questions about new pharmaceuticals: first, is the product expected to be cost-effective on the basis of existing evidence?

TL;DR: Anemia may substantially increase health-care costs at a level that is economically very relevant, despite the fact that these patients may comprise only one tenth of the overall anemic population.

TL;DR: The RLSQoL is a valid and reliable measure of the impact of RLS on QoL and is responsive to short-term changes in symptom severity and appears to be an appropriate tool for trial-based assessments of treatments for RLS.

TL;DR: This probabilistic model-based economic evaluation demonstrates how clinical trial data can be combined and integrated with country-specific information about resource utilization and unit cost to assess the cost-effectiveness of bronchodilators in COPD patients.

TL;DR: Preliminary evidence demonstrates that the IDEEL will be sensitive to QoL changes over time, although further testing in controlled longitudinal studies is needed.

TL;DR: HODaR represents a new approach to accessing patient data, and gathers both routine and survey-based data, which can produce health outcomes data at relatively low cost.

TL;DR: Piggyback evaluations can be an appropriate means to measure the economic impact of medical interventions, provided that the methodologic challenges are acknowledged and addressed within the context of each individual study.

TL;DR: The BSW is a useful tool to capture patients' global impressions of three key elements of treatment outcome: a perceived benefit, satisfaction with treatment and the willingness to continue treatment, and can facilitate patient-physician communication as well as be informative to researchers.

TL;DR: Good reliability and validity of the refined (14-item) PPCI can be useful as a research tool for assessment of the physicians' perspective about a physician-pharmacist relationship.

TL;DR: Breast cancer recurrence and contralateral breast cancer lead to substantial increases in costs, amounting to approximately $11,000-19,000 over 10 years depending on type.

TL;DR: The results will enable interpretation of treatment group effects in a clinical trial setting, and they can be used to estimate sample size or power when designing future studies.

TL;DR: Anemia among cancer patients receiving chemotherapy is associated with a substantial burden in terms of direct medical costs and Implications for the treatment of anemia are suggested and should be confirmed in prospective studies.

TL;DR: An increase in the number of publications focusing on patient satisfaction (excluding studies where satisfaction may be one of several endpoints) parallels the rise of “the patient as an active consumer of health-care services rather than merely as a passive recipient”.

TL;DR: Hospital treatment costs are found to be higher for obese and overweight patients than for normal weight patients indicating potential cost savings especially on indirect costs by effective, safe and low cost weight-loss intervention.

TL;DR: The Cancer Therapy Satisfaction Questionnaire (CTSQ) was designed for adults with a wide range of cancer types and stages, receiving a variety of cancer treatment formulations and assesses seven domains: Expectations of cancer therapy, Feelings about side effects, Oral cancer therapy adherence, Convenience, Satisfaction with cancer Therapy, Stopping cancer therapy and Reasons for nonadherence.

TL;DR: Adaptive conjoint analysis was successful in predicting HIV treatment preferences under different medication scenarios, and resistance, regimen convenience, and sleep disturbance would likely make the most difference in the perceived value of a third-agent HIV medication.

TL;DR: Considering the impact of vaccination onvaricella morbidity and costs, a routine varicella vaccination program appears to be cost saving in Germany and France from both a societal and a third-party payer perspective.

TL;DR: Health researchers need to better justify the inclusion of these outcomes in clinical trials and highlight the added value of PRO data; while the regulators should develop harmonized procedures and capacities to adequately appraise the submitted information.

TL;DR: The economic burden of osteoporosis-related fractures on state Medicaid budgets is substantial and the estimated incremental cost was $5370 for the subset of patients who were eligible for Medicare.

TL;DR: R-CHOP significantly increases mean OS up to 4 years compared with CHOP, and its cost-effectiveness ratio compares favorably with other oncology treatments in widespread use.